

***CALLS FOR PROPOSALS FOR RESEARCH AND INNOVATION  
ON COVID-19: EU Member States and Associated Countries***  
*update 17 March 2020*

**Contents**

FRANCE .....	2
AGENCE NATIONALE DE LA RECHERCHE.....	2
GERMANY.....	2
FEDERAL MINISTRY OF EDUCATION AND RESEARCH .....	2
NORWAY .....	3
RESEARCH COUNCIL OF NORWAY .....	3
SWITZERLAND .....	3
SWISS NATIONAL SCIENCE FOUNDATION (SNSF) .....	3
INNOVATIVE MEDICINES INITIATIVE (IMI) .....	4
CALL FOR PROPOSALS ON THE CORONAVIRUS .....	4

## FRANCE

### AGENCE NATIONALE DE LA RECHERCHE

#### FLASH CALL COVID-19

**Deadline:** 23 March 2020

**Total budget:** 3 million euros (initial)

**Description:** the application process must be carried out by the scientific coordinator of the project on behalf of a group or a consortium. The peer review will be carried out by a scientific multidisciplinary evaluation committee, without external experts. A list of projects will then be selected by a steering committee on the basis of recommendations given by the evaluation committee.

Each project can be financed for a maximum of 200.000 euros for a period of 12 to 18 months.

<https://anr.fr/fileadmin/aap/2020/aap-flash-covid-2020.pdf>

## GERMANY

### FEDERAL MINISTRY OF EDUCATION AND RESEARCH

#### RESEARCH ON COVID-19 IN THE WAKE OF SARS-COV-2 OUTBREAK

**Deadline:** 11 May 2020

**Budget:** Modules 1, 2, 3: up to 2 million euros per project; Module 4: up to 50,000 euros per project

**Description:** funding will be provided for individual projects and, exceptionally, small research consortia (up to 3 partners). Funding will also be provided for individual projects by German applicants who wish to participate in international research consortia within the framework of the global research response to COVID-19 coordinated by the WHO. The funding covers a period of 18 months; the BMBF intends to share relevant data with international sponsors who are WHO-coordinated in GloPID-R. Funded projects must be oriented on applied research and development: projects relying mainly on basic research are not eligible for funding. Cooperation with thematically related R&D projects abroad is possible, although the international partner(s) must in principle have their own funding for their part(s) of the project. However, if cooperation with a foreign working group is necessary for the processing of an essential work package, personnel and material resources in the form of a subcontract are eligible for funding.

The call is composed of four modules:

- Module 1 - *Combating COVID-19 through early clinical studies for the application of already known therapeutic approaches to Sars-CoV-2;*
- Module 2 - *Control of COVID-19 through new therapeutic and diagnostic approaches;*
- Module 3 - *Research that contributes to the understanding of the virus and its spread;*
- Module 4 - *Support of already ongoing research projects on coronaviruses.*

[https://www.dlr.de/pt/Portaldata/45/Resources/Dokumente/GF/2020\\_03\\_02\\_Call\\_announcement\\_covid19.pdf](https://www.dlr.de/pt/Portaldata/45/Resources/Dokumente/GF/2020_03_02_Call_announcement_covid19.pdf)

## NORWAY

### RESEARCH COUNCIL OF NORWAY

COVID-19 EMERGENCY CALL FOR PROPOSALS: PROJECT OUTLINES FOR CALL CONCERNING THE FIGHT AGAINST CORONAVIRUS DISEASE (COVID-19)

**Deadline:** 16 March 2020 (proposal outline), 31 March 2020 (full proposal)

**Total budget:** 30 million Norwegian kroner (2.76 million euros)

**Description:** the call for proposals is based on the recent research priorities defined by the WHO. International collaboration with research groups in other countries, including those funded by GLOPID-R member organisations to foster larger-scale studies, is encouraged. Project outlines may only be submitted by approved Norwegian research organisations; these organisations may submit project outlines in cooperation with the public and/or private sectors, other public entities and/or private organisations. The Research Council can provide 1 to 5 million Norwegian kroner (92,600 to 463,000 euros) per project under this call. Each applicant must provide at least 20 % own financing.

<https://www.forskningsradet.no/en/call-for-proposals/2020/emergency-call-proposals-project-outline-covid-19/>

## SWITZERLAND

### SWISS NATIONAL SCIENCE FOUNDATION (SNSF)

*SPECIAL CALL ON CORONAVIRUSES*

**Deadline:** 25 March 2020

**Total budget:** 5 million Swiss francs (4.73 million euros)

**Description:** the SNSF is supporting projects involving research into coronaviruses to tackle the current crisis and prepare for likely future epidemics. The call takes into account the agenda set by the World Health Organisation (WHO) and is in line with the priorities defined by the Federal Office of Public Health (FOPH).

The SNSF will forward the project proposals to international experts for evaluation. Applicants may request up to 300,000 francs (282,700 euros) for projects lasting up to 24 months. Bigger grants are conceivable, provided the applicant has good reasons for requesting a higher amount. On completion of the project, research data must be made available for researchers and authorities worldwide and without delay.

<http://www.snf.ch/en/funding/programmes/coronavirus/Pages/default.aspx#News>

## INNOVATIVE MEDICINES INITIATIVE (IMI)

### CALL FOR PROPOSALS ON THE CORONAVIRUS

**Deadline:** 31 March 2020

**Total budget:** 45 million euros (+45 million euros from pharmaceutical companies through in-kind contributions)

**Description:** funding will come from the EU's Horizon 2020 research and innovation programme, and will fund the involvement in the projects of organisations such as universities and small and medium-sized enterprises (SMEs). Large pharmaceutical companies that are members of EFPIA and IMI2 Associated Partners will not receive EU funding through this Call, but are expected to contribute to the projects with their own resources and funds. Proposals will be assessed by independent experts, and the funding will go to the consortia with the highest scores. Applicants who want to score well will need to demonstrate their ability to develop tests and/or treatments for COVID-19, and maximise the added value of the IMI2 public-private partnership by including contributing partners in their consortium.

<https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-21>